Steroids for the Longest Bypass Run on the Schedule, Against Two Trials That Found No Benefit
A 61-year-old man facing a hemiarch replacement with circulatory arrest is looking at one of the longest bypass exposures the team will run all year. The two largest trials of prophylactic steroids in cardiac surgery both came back negative — and the question is whether his case is different enough to matter.
Roger P., a 61-year-old man, manages a small commercial fishing fleet out of a coastal town and was found to have an ascending aortic aneurysm extending into the proximal arch on a CT scan ordered after a routine physical exam picked up a new murmur — asymptomatic until the imaging made the extent of the problem clear. His surgeon has planned a hemiarch replacement requiring a period of deep hypothermic circulatory arrest, a technically demanding operation that will keep him on bypass considerably longer than a routine CABG or single-valve case, given the cooling and rewarming time circulatory arrest itself requires on top of the repair. He has no diabetes and a fasting glucose of 92, which will matter shortly for reasons having nothing to do with his aorta.
That anticipated bypass duration is directly relevant to a question the team is discussing before he ever reaches the OR: whether to give prophylactic corticosteroids to blunt the systemic inflammatory response bypass itself provokes, an inflammatory burden that scales with time on the circuit. The two largest trials ever built to test this — SIRS, with roughly 7,500 patients on methylprednisolone, and DECS, with roughly 4,500 on dexamethasone — both came back negative on their primary composite outcomes. Neither, though, enrolled a population whose average time on bypass resembles his, and neither was designed to isolate patients undergoing circulatory arrest. His normal glucose tolerance is the other half of it: SIRS's clearest documented harm was worse hyperglycemia in the steroid arm, and that is precisely the adverse signal his own metabolic baseline gives him more room to absorb than the average trial participant had. Two null primary outcomes, and a patient sitting outside those populations on the one dimension that would most plausibly matter.
Deciding on steroids before the longest bypass run on the schedule
I don't think we should give prophylactic steroids. SIRS and DECS are the two largest trials ever built to answer this question, and both came back negative on their primary composite outcomes. SIRS specifically found significantly worse hyperglycemia in the steroid arm — a real, documented harm, not just an absence of benefit.
I hear the primary-outcome point, but DECS's secondary outcomes told a more nuanced story — dexamethasone reduced postoperative infection risk and shortened time to extubation, even though the primary composite didn't move. His bypass time today is going to run well past what most of that trial's participants experienced, given the circulatory arrest a hemiarch requires.
I don't think it's unreasonable to think a longer inflammatory exposure is exactly the scenario where a modest anti-inflammatory effect might show up more clearly than it did in an average-severity trial population. I'm not disputing the primary result — I'm asking whether his case sits outside what the trial's average patient actually looked like.
That's a fair question to raise, and I don't have direct trial data on bypass-duration subgroups to answer it definitively either way — you're right that neither trial was designed to isolate patients with circulatory arrest specifically. I'll concede the secondary-outcome signal is real, even if it's a weaker basis than a primary-outcome benefit would be.
Given his normal glucose tolerance removes SIRS's main documented harm concern for him specifically, I'm willing to support a single intraoperative dexamethasone dose — not because I think the evidence is strong, but because his case genuinely sits outside what either trial's average patient looked like, and the harm signal that worried me most doesn't apply as clearly to him.
Agreed: a single intraoperative dexamethasone dose given before bypass, with intensified glucose monitoring through the case and into the ICU given SIRS's documented hyperglycemia signal, even though his own risk for that specific harm was judged low.
Not agreed as a general prescribing rule: at what bypass-duration threshold the secondary-outcome argument for steroids should routinely apply for future patients, since neither trial was designed to answer that question directly. The pharmacologist's original skepticism about the primary-outcome evidence was not retracted, only judged less decisive for a patient whose case genuinely falls outside the trials' typical severity range.